Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Amgen Inc patents


Recent patent applications related to Amgen Inc. Amgen Inc is listed as an Agent/Assignee. Note: Amgen Inc may have other listings under different names/spellings. We're not affiliated with Amgen Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Amgen Inc-related inventors


Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof

The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.. ... Amgen Inc

Low-viscosity, high concentration evolocumab formulations and methods of making the same

Provided herein are formulations of pcsk9-binding polypeptides, such as those comprising evolocumab, that comprise n-acetyl arginine and have reduced viscosities when compared to formulations lacking n-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. ... Amgen Inc

Interleukin-2 muteins for the expansion of t-regulatory cells

Provided herein are il-2 muteins and il-2 mutein fc-fusion molecules that preferentially expand and activate t regulatory cells and are amenable to large scale production. Also provided herein are variant human igg1 fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at n297. ... Amgen Inc

Imaging system for counting and sizing particles in fluid-filled vessels

A system is described to facilitate the characterization of particles within a fluid contained in a vessel using an illumination system that directs source light through each vessel. One or more optical elements may be implemented to refract the source light and to illuminate the entire volume of the vessel. ... Amgen Inc

Bispecific-fc molecules

Described herein is a bispecific molecule containing an fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.. ... Amgen Inc

Charged depth filtration of antigen-binding proteins

Methods of producing an aqueous formulation of an antigen-binding protein or enhancing re-oxidation of an antigen-binding protein are disclosed. The methods comprise (a) contacting an aqueous solution comprising antigen-binding protein molecules with a charged depth filter under conditions sufficient to enhance re-oxidation of the antigen-binding protein molecules and achieve a decrease in the percentage of reduced antigen-binding protein molecules, compared to the percentage of reduced antigen-binding protein molecules observed prior to step (a); and (b) optionally, measuring the amount or relative amount of reduced antigen-binding protein molecules. ... Amgen Inc

Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

. . The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (bace) activity. The compounds have a general formula i: wherein variables a4, a5, a6, a7, and each of ra, rb, r1, r2, r3, r8 r9 and r10 of formula i, independently, are defined herein. ... Amgen Inc

Antibodies targeting cdh19 for melanoma

The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human cdh19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. ... Amgen Inc

Drug delivery system with electromagnetic field generator

A drug delivery device (100) includes a base (102) having a first region (104) with a drug delivery assembly (106) associated therewith. The drug delivery device also includes an antenna (112) disposed in the first region to radiate an electromagnetic field, the base defining a plane (114) and the antenna disposed in the plane of the base, and an electromagnetic field generator (116) selectively coupled to the antenna.. ... Amgen Inc

Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement

A drug delivery device includes a casing and a storage container with a dose delivery member, at least a portion of which extends through an opening in the casing. A guard is movable relative to the casing between extended and retracted positions. ... Amgen Inc

Kras g12c inhibitors and methods of using the same

Provided herein are kras g12c inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.. ... Amgen Inc

Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an ang2 inhibitor in combination with a taxane.. . ... Amgen Inc

Gastro-retentive modified release dosage forms for oprozomib and process to make thereof

This disclosure features gastro-retentive (gr) modified release pharmaceutical dosage forms (e.g., solid dosage forms, e.g., tablets, e.g., bilayer tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the dosage form.. . ... Amgen Inc

Methods and apparati for nondestructive detection of undissolved particles in a fluid

The apparati, methods, and computer program products disclosed herein can be used to nondestructively detect undissolved particles, such as glass flakes and/or protein aggregates, in a fluid in a vessel, such as, but not limited to, a fluid that contains a drug.. . ... Amgen Inc

05/24/18 / #20180142029

Human cgrp receptor binding proteins

Antigen binding proteins that bind to human cgrp receptor (cgrp r) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. ... Amgen Inc

05/24/18 / #20180142021

Bispecific antibody constructs for cdh3 and cd3

The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human cdh3 on the surface of a target cell and a second binding domain which binds to human cds on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

05/24/18 / #20180140611

Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Disclosed herein are combination therapies for the treatment of heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, and a sinus node if current inhibitor, such as ivabradine. Also disclosed herein are compositions comprising a cardiac myosin activator and a sinus node if current inhibitor.. ... Amgen Inc

05/17/18 / #20180134805

Material and methods for treating or preventing her-3 associated diseases

Described herein are materials and methods for treating subjects having a her-3 associated disease, by administering a first agent that binds to her-3, in combination with a second agent that binds and/or inhibits another member of the her family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.. ... Amgen Inc

05/17/18 / #20180133106

Drug cassette, autoinjector, and autoinjector system

A cassette for use with an injector has a housing, and a cassette identification arrangement (cassette id) defining a code containing information about the cassette that is detectable and decipherable by an injector. The cassette may further have a sleeve movably disposed within the housing, for holding a drug container, and a locking arrangement for interlocking the sleeve with the housing. ... Amgen Inc

04/19/18 / #20180105589

Homogeneous antibody populations

The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant igg2 antibody proteins.. ... Amgen Inc

04/19/18 / #20180105532

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. . ... Amgen Inc

04/12/18 / #20180098940

Pediatric formulation

The present invention is directed to pediatric formulation of (r)-n-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as cinacalcet hc1) and method of administering the same.. . ... Amgen Inc

04/12/18 / #20180098914

Drug cassette, autoinjector, and autoinjector system

A cassette for use with an injector has a housing, and a cassette identification arrangement (cassette id) defining a code containing information about the cassette that is detectable and decipherable by an injector. The cassette may further have a sleeve movably disposed within the housing, for holding a drug container, and a locking arrangement for interlocking the sleeve with the housing. ... Amgen Inc

04/05/18 / #20180094055

Human pac1 antibodies

Antibodies and antigen-binding fragments thereof that bind to human pac1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. ... Amgen Inc

04/05/18 / #20180092898

Processes of making and crystalline forms of a mdm2 inhibitor

The present invention provides processes for making 2-((3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((s)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.. ... Amgen Inc

03/29/18 / #20180087079

Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.. ... Amgen Inc

03/22/18 / #20180080452

Stable liquid formulation of amg 416 (etelcalcetide)

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.. . ... Amgen Inc

03/22/18 / #20180079790

Growth differentiation factor 15 (gdf-15) constructs

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. ... Amgen Inc

03/22/18 / #20180079777

Solution phase method for preparing etelcalcetide

The instant disclosure is directed to solution phase fragment coupling methods for preparing etelcalcetide and its pharmaceutically acceptable salts.. . ... Amgen Inc

03/22/18 / #20180078532

Immediate release formulations for oprozomib

This disclosure features immediate release pharmaceutical formulations (e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.. . ... Amgen Inc

03/15/18 / #20180072791

Variant activin receptor

The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. ... Amgen Inc

02/08/18 / #20180037603

Capture purification processes for proteins expressed in a non-mammalian system

. . Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. ... Amgen Inc

02/08/18 / #20180036476

Drug delivery device with vacuum assisted securement and/or feedback

A drug delivery device includes a housing with at least one pressure communication channel or aperture, which distributes a negative fluid pressure across its base to draw tissue against the device. The device can also include a porous, adhesive layer over the channel(s) or aperture(s), for attaching to tissue. ... Amgen Inc

02/01/18 / #20180030132

Methods of treatment using an interferon gamma inhibitor

The invention encompasses methods of treatment of interferon gamma (ifn-γ)-mediated diseases using ifn-γ inhibitors, such as anti-huifn-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the ifn-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huifn-γ antibody.. ... Amgen Inc

02/01/18 / #20180030116

Variants of tissue inhibitor or metalloprotienase type three (timp-3), compositions and methods

The application concerns tissue inhibitor of metalloproteinase 3 (timp-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of timp-3 with specific amino acid substitutions in order to introduce n-linked glycosylation sites.. . ... Amgen Inc

02/01/18 / #20180028747

Device and method for making aseptic connections

The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). ... Amgen Inc

01/25/18 / #20180021521

Drug delivery device with a rotatable drive mechanism

A rotatable drive mechanism for a drug delivery device may include a lead screw having a distal end, a proximal end, and external threads, a bearing, and a ball screw driver having a threaded aperture wherein the threaded aperture is configured to rotatably engage with the external threads of the lead screw. The mechanism may further include a biasing device disposed between the bearing and the ball screw driver generating an axial drive force, and an activation device configured to release the biasing device and allowing the biasing device to expand from a compressed position to an extended position through which the axial drive force of the biasing device causes the ball screw driver to axially move toward the distal end of the lead screw and rotate the lead screw such that a threaded engagement between the lead screw and the ball screw driver bears the axial drive force.. ... Amgen Inc

01/04/18 / #20180002733

Methods for increasing mannose content of recombinant proteins

The present invention relates to methods of modulating the mannose content of recombinant proteins.. . ... Amgen Inc

01/04/18 / #20180002450

Antibody constructs for cdh19 and cd3

The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human cdh19 on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

01/04/18 / #20180002417

Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.. . ... Amgen Inc

01/04/18 / #20180000898

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease. ... Amgen Inc

12/28/17 / #20170369837

Feed media

The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.. ... Amgen Inc

12/28/17 / #20170368260

Drug delivery device with live button or user interface field

A drug delivery device includes a container for storing a drug, the container having a stopper for expelling the drug; an injection drive comprising an energy source for directly or indirectly acting on the stopper to expel the drug; a sensor for detecting contact between the drug delivery device and a body of a patient; and a user interface (ui) for activating or causing the activation of the injection drive. The device is operative for drawing attention to the ui, if the sensor detects contact between the drug delivery device and the body of the patient, to thereby indicate that the injection drive is ready to be activated, which activation is the next step in the drug administration process.. ... Amgen Inc

12/28/17 / #20170368170

Self-buffering protein formulations

The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. ... Amgen Inc

12/21/17 / #20170362625

Process for manipulating the level of glycan content of a glycoprotein

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.. . ... Amgen Inc

12/21/17 / #20170361015

Drug delivery device with proximity sensor

A drug delivery device, in the form of an injector, may include one of a number of systems for limiting the delivery of a medical fluid or drug product in case of movement of (e.g., removal of) the injector relative to the patient as determined by a proximity sensor. The drug delivery system may in the alternative or in addition include systems for indicating the amount of medical fluid or drug product delivered (or not delivered) in case of movement of (e.g., removal of) the injector relative to the patient as determined by the proximity sensor. ... Amgen Inc

12/21/17 / #20170360857

Stable frozen virus formulation

A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures.. . ... Amgen Inc

12/14/17 / #20170355741

Production of glycoproteins using manganese

Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.. . ... Amgen Inc

12/07/17 / #20170349668

Optimized cross-species specific bispecific single chain antibody contructs

The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the t cell surface antigen cd3 via a second binding domain, wherein serum albumin is fused to the c-terminus of the antibody construct. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said vector. ... Amgen Inc

11/30/17 / #20170342155

Methods and compositions relating to anti-ccr7 antigen binding proteins

. . The present invention provides compositions and methods relating to antigen binding proteins against ccr7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.. . ... Amgen Inc

11/23/17 / #20170333559

Reducing viscosity of pharmaceutical formulations

A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.. ... Amgen Inc

11/16/17 / #20170327581

Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains

The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian t-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells are also contemplated.. ... Amgen Inc

10/26/17 / #20170306033

Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof

. . The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human cgrp receptor and the human pac1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. ... Amgen Inc

10/12/17 / #20170291929

Growth differentiation factor 15 (gdf-15) polypeptides

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. ... Amgen Inc

10/05/17 / #20170281625

Methods of treating heart failure

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the apj receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.. ... Amgen Inc

09/28/17 / #20170275373

Bispecific single chain antibody construct with enhanced tissue distribution

The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the t cell surface antigen cd3 via a second binding domain, the construct comprising two fcrn binding peptides. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said vector. ... Amgen Inc

09/28/17 / #20170275370

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. ... Amgen Inc

09/28/17 / #20170275365

Alpha-4-beta-7 heterodimer specific antagonist antibody

There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.. . ... Amgen Inc

09/21/17 / #20170267775

Cd27l antigen binding proteins

. . The present invention relates to cd27l antigen binding proteins, such an antibodies, polynucleotides encoding said cd27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with cd27l expression.. . ... Amgen Inc

09/21/17 / #20170267769

St2 antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof. ... Amgen Inc

09/07/17 / #20170253889

Promoter and regulatory elements for improved expression of heterologous genes in host cells

Disclosed are a recombinant expression vector and a host cell that contains the vector.. . ... Amgen Inc

08/31/17 / #20170247476

Protease-activatable bispecific proteins

Described herein are protease-activatable proteins (pabps), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such pabps and methods of making and using pabps.. ... Amgen Inc

08/31/17 / #20170247451

Human pac1 antibodies

Antibodies and antigen-binding fragments thereof that bind to human pac1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. ... Amgen Inc

08/17/17 / #20170233467

Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies

The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.. . ... Amgen Inc

08/10/17 / #20170224934

Drug injection device with visual and audio indicators

A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container. The device includes visual and/or audible indicators for indicating that the correct depth of needle penetration has been achieved and that drug injection/extrusion has been started and/or completed. ... Amgen Inc

08/03/17 / #20170218079

Psma and cd3 bispecific t cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific fc modality characterized by comprising a first domain binding to psma, a second domain binding to an extracellular epitope of the human and the macaca cd3ε chain and a third domain, which is the specific fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.. ... Amgen Inc

08/03/17 / #20170218078

Bispecific t cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the macaca cd3ε chain and a third domain, which is the specific fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.. ... Amgen Inc

08/03/17 / #20170218077

Bcma and cd3 bispecific t cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific fc modality characterized by comprising a first domain binding to bcma, a second domain binding to an extracellular epitope of the human and/or the macaca cd3ε chain and a third domain, which is the specific fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.. ... Amgen Inc

08/03/17 / #20170218067

Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof

The invention described herein is related to antibodies directed to the antigen tim-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen tim-1. ... Amgen Inc

08/03/17 / #20170218062

Methods for treating crohn's disease using an anti-il23 antibody

The invention relates to products and methods for treating crohn's disease. The products relate to antibodies that inhibit native human il-23 while sparing il-12. ... Amgen Inc

07/27/17 / #20170210792

Antibody formulations

Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.. . ... Amgen Inc

07/27/17 / #20170209582

Protein formulations

The present disclosure provides solid protein formulations that are stable over a variety of temperatures for extended time periods. The present disclosure also provides methods of making and using these formulations.. ... Amgen Inc

07/27/17 / #20170209571

Pharmaceutical composition comprising bispecific antibody constructs

The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.. . ... Amgen Inc

07/20/17 / #20170202909

Formulated receptor polypeptides and related methods

Disclosed herein is an activin receptor iib-based composition and related methods of use, e.g., to treat solid tumors. Also disclosed are methods of manufacturing the compound and formulation.. ... Amgen Inc

07/13/17 / #20170198059

Crystalline antibody formulations

Described herein are anti-pcsk9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.. . ... Amgen Inc

07/13/17 / #20170198058

Crystalline antibody formulations

Described herein are anti-pcsk9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.. . ... Amgen Inc

07/06/17 / #20170190793

Carrier immunoglobulins

Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. ... Amgen Inc

07/06/17 / #20170190739

Method for preparing amg 416

A method for preparing amg 416, or a pharmaceutically acceptable salt thereof, is provided. Amg 416 is a synthetic, eight amino-acid selective peptide agonist of the calcium sensing receptor. ... Amgen Inc

06/29/17 / #20170183417

Antibodies to opgl

. . Antibodies that interact with osteoprotegerin ligand (opgl) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to opgl are described. ... Amgen Inc

06/29/17 / #20170183412

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c. ... Amgen Inc

06/29/17 / #20170182253

Autoinjector with shock reducing elements

An injection device, method, and system for drug delivery includes a primary container for storing a drug, the container having a stopper movably disposed in the container for expelling the drug, an injection drive mechanism comprising a plunger for acting on the stopper and an energy source for exerting a force on the plunger to cause the plunger to act on the stopper to expel the drug, the force causing the plunger to accelerate to a velocity prior to acting on the stopper, and a damping mechanism for reducing the velocity of the plunger prior to acting on the stopper. The damping mechanism can include a dashpot or an energy absorbing material associated with the plunger. ... Amgen Inc

06/29/17 / #20170182016

Biomarkers and use of met inhibitor for treatment of cancer

The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as met amplification and high met expression for patient selection.. . ... Amgen Inc

06/15/17 / #20170166973

Nucleic acid biomarker and use thereof

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing hrg gene expression at an mrna level in the human subject and administering a treatment comprising an anti-her3 antibody to the human subject whose hrg gene expression at an mrna level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing hrg gene expression at an mrna level in the human subject and withholding a treatment comprising an anti-her3 antibody to the human subject whose hrg gene expression at an mrna level is assessed as low.. ... Amgen Inc

06/15/17 / #20170166942

Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the n-glycosylation pathway.. ... Amgen Inc

06/15/17 / #20170166654

Protein biomarker and uses thereof

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing hrg gene expression at a protein level in the human subject and administering a treatment comprising an anti-her3 antibody to the human subject whose hrg gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing hrg gene expression at a protein level in the human subject and withholding a treatment comprising an anti-her3 antibody to the human subject whose hrg gene expression at a protein level is assessed as low. ... Amgen Inc

06/15/17 / #20170165373

Bcma antigen binding proteins

The present invention relates to bcma (b-cell maturation antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to bcma antibody drug conjugates.. ... Amgen Inc

06/08/17 / #20170157566

Process control systems and methods for use with filters and filtration processes

Systems and methods used to control tangential flow filtration are provided, including control systems and methods for use with connected systems with upstream processing units, such as chromatography processing units, in fluid communication with a tangential flow filtration processing unit. Also included are control systems and methods for performing continuous concentration using single-pass tangential flow filtration with permeate flow control.. ... Amgen Inc

06/01/17 / #20170151338

Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

The present invention provides for improved compositions comprising a pegstnf-r1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cp) and improved stability.. . ... Amgen Inc

05/18/17 / #20170137538

Pharmaceutical compositions with resistance to soluble cea

The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human cd3, and a second binding domain specifically binding to human cea, where the second binding domain comprises at least a part of the cdr-h3 or the complete cdr-h3 of murine monoclonal antibody a5b7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human cd3 antigen and the human cea antigen are disclosed.. ... Amgen Inc

05/18/17 / #20170137485

Interleukin-2 muteins for the expansion of t-regulatory cells

Provided herein are il-2 muteins and il-2 mutein fc-fusion molecules that preferentially expand and activate t regulatory cells and are amenable to large scale production. Also provided herein are variant human igg1 fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at n297. ... Amgen Inc

05/11/17 / #20170129961

Antibody constructs for cd70 and cd3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human cd70 on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

05/04/17 / #20170124285

Devices and methods for assisting a user of a drug delivery device

Devices and methods are disclosed for assisting a user of a drug delivery device with an application executing on a mobile computing device. The mobile computing device may receive information from the drug delivery device related to its condition and/or operation and subsequently select an informational and/or instructional prompt to be displayed to the user based on the received information. ... Amgen Inc

05/04/17 / #20170124284

Drug delivery system and method of use

A drug delivery system is disclosed that includes a drug delivery device having a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. The drug delivery system may further include one or more sensors coupled to the drug delivery device, a wireless transmitter, and a controller coupled to the one or more sensors and the wireless transmitter. ... Amgen Inc

05/04/17 / #20170122947

Risk-stratification of b-precursor acute lymphoblastic leukemia patients

The present invention relates to a method for risk-stratifying subjects suffering from b-precursor acute lymphoblastic leukemia (all), wherein said subjects are intended for a therapy comprising administration of a cd3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 μl in a csf sample from said subject. ... Amgen Inc

05/04/17 / #20170119969

Controllable drug delivery system and method of use

A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. ... Amgen Inc

04/27/17 / #20170114381

Methods for harvesting mammalian cell cultures

The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.. . ... Amgen Inc

04/20/17 / #20170107288

Dual receptor antagonistic antigen-binding proteins and uses thereof

This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. ... Amgen Inc

04/20/17 / #20170107255

Apelin polypeptides

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.. ... Amgen Inc

04/20/17 / #20170106146

Autoinjector with low energy plunger loading

An injection device, method, and system for drug delivery includes a container for storing a drug, the container having a stopper movably disposed in the container for expelling the drug; an injection drive mechanism having a plunger for acting on the stopper and an energy source having a first selected potential energy for exerting a force on the plunger to cause the plunger to act on the stopper to expel the drug; and a plunger loading mechanism for substantially preventing the plunger from accelerating to a predetermined velocity before it acts on the stopper. The plunger loading mechanism may be a spring having a second selected potential energy for reducing or eliminating a distance between the plunger and the stopper, prior to the plunger accelerating to the velocity. ... Amgen Inc

04/13/17 / #20170103186

Systems and methods for supporting patient use of a drug delivery device

Systems and methods are disclosed herein for supporting a patient's use of a drug delivery device. The patient may be associated with a support group via, for example, a social networking service for the purpose of increasing the likelihood that the patient will comply with a treatment regimen. ... Amgen Inc

04/06/17 / #20170098058

Systems and methods for remotely processing data collected by a drug delivery device

Systems and methods are disclosed for processing sensor data collected by a drug delivery device with an external computing device. The drug delivery device may include a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. ... Amgen Inc

03/30/17 / #20170088874

Methods for increasing mannose content of recombinant proteins

. . The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.. . ... Amgen Inc

03/30/17 / #20170088620

Asgr inhibitors

Antigen binding proteins that interact with asgr, asgr-1 and/or asgr-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of asgr, asgr-1 and/or asgr-2 antigen binding proteins. ... Amgen Inc

03/23/17 / #20170082608

Assay for detecting th1 and th2 cell populations

The present disclosure relates to a method for detecting t helper cell or ctl subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the t helper cells and ctls in a therapeutic or adverse direction.. ... Amgen Inc

03/23/17 / #20170081668

Method of modulating fibroblast accumulation or collagen deposition

The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.. ... Amgen Inc

03/23/17 / #20170081398

Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and cdrs of the antibodies, as well as methods of making and using the antibodies.. ... Amgen Inc

03/23/17 / #20170081382

Interleukin-2 muteins for the expansion of t-regulatory cells

Provided herein are il-2 muteins and il-2 mutein fc-fusion molecules that preferentially expand and activate t regulatory cells and are amenable to large scale production. Also provided herein are variant human igg1 fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at n297. ... Amgen Inc

03/16/17 / #20170073408

Anti-activin a antibodies and uses thereof

The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments. ... Amgen Inc

03/16/17 / #20170072143

Drug delivery device

A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. ... Amgen Inc

03/09/17 / #20170066845

Proteins specific for baff and b7rp1

Described herein are bispecific proteins specific for baff and b7rp1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.. . ... Amgen Inc

02/23/17 / #20170051057

Antibodies to madcam

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to madcam, preferably human madcam and that function to inhibit madcam. The invention also relates to human anti-madcam antibodies and antigen-binding portions thereof. ... Amgen Inc

02/23/17 / #20170049895

Pharmaceutical formulations

A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.. . ... Amgen Inc

02/09/17 / #20170037149

Antibody constructs for flt3 and cd3

. . . . The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human flt3 on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

02/09/17 / #20170037133

Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers

The present invention provides an inhibitor against cd112 (nectin-2, pvrl2), cd155 (pvr), galectin-9, tim-3 and/or tigit for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (aml). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against cd112 (nectin-2, pvrl2), cd155 (pvr), galectin-9, tim-3 and/or tigit and a car t cell. ... Amgen Inc

02/09/17 / #20170037130

Antibody constructs for dll3 and cd3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human dll3 on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

02/02/17 / #20170029512

Antibody constructs for egfrviii and cd3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human egfrviii on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

02/02/17 / #20170029502

Antibody constructs for msln and cd3

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human msln on the surface of a target cell and a second binding domain which binds to human cd3 on the surface of a t cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. ... Amgen Inc

02/02/17 / #20170029443

Polymorphic forms and co-crystals of a c-met inhibitor

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1r)-1-[8-fluoro-6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6h)-one, which is an inhibitor of c-met.. ... Amgen Inc

01/26/17 / #20170022285

Gitr antigen binding proteins

Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. ... Amgen Inc

01/19/17 / #20170015750

Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4. ... Amgen Inc

01/19/17 / #20170015743

Anti-erythropoietin antibodies

The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.. ... Amgen Inc

01/05/17 / #20170002079

St2 antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof. ... Amgen Inc

01/05/17 / #20170002070

Human il-23 antigen binding proteins

Antigen binding proteins that bind to human il-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of il-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.. ... Amgen Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amgen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amgen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###